The present invention relates to four distinct crystalline polymorphs of a monohydrate of Compound A having the following chemical structure: 1 These four polymorphic forms, herein referred to as Forms I, II, III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.